Goldman: ' the inability to fully screen at-risk patients could be a factor in the competitive dynamics in ATTR'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $8.00 price target on Intellia Therapeutics (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
